Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
Document › Details

CureVac AG. (1/6/16). "Press Release: CureVac to Present at the 34th Annual J.P. Morgan Healthcare Conference". Tübingen.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation CureVac AG
  Group CureVac (Group)
  Organisation 2 J.P. Morgan Investment Management Inc.
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 34th Annual Healthcare Conference 2016 San Francisco
  Product 2 RNA-based therapeutic
Index term Index term CureVac–JPMorgan Chase: investor conference, 201601 supply service CureVac presents at JP Morgan Healthcare Conference 2016
Persons Person Hoerr, Ingmar (CureVac 200601 CEO + co-founder)
  Person 2 Lauterbach, Verena (CureVac GmbH 201603 Senior Director Communications)

> CureVac presenting at the leading healthcare conference of the year following numerous financial, clinical and corporate milestones in 2015

CureVac, a clinical-stage biopharmaceu-tical company pioneering the field of mRNA-based technology, today announced that the company will present at the 34th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA.

Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, will provide an overview of the company’s business, industry-leading mRNA technology platform and clinical-stage development pipeline during his presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Dr. Hoerr will for the first time present data from the first-ever clinical proof-of-concept trial of an mRNA-based prophylactic vaccine.

Event: 34th Annual J.P. Morgan Healthcare Conference
Date: Tuesday, January 12, 2016
Time: 02:00 PM - 02:25 PM (Pacific Time)
Location: Westin St. Francis Hotel, San Francisco, CA.
Room: Elizabethan C

2015 was a transformative year for CureVac, highlighted by the largest equity investment of the Gates Foundation completed in March and the company’s recent $110M financing (completed November 2015), the publication of peer-reviewed studies validating its mRNA technology platform, and the establishment of collaborative agreements including those with IAVI (International AIDS Vaccine Initiative), the Bill & Melinda Gates Foundation and numerous vaccine-development projects.

In 2016 CureVac anticipates achieving multiple clinical and operational milestones, including the reporting of clinical data from its placebo controlled double blinded Phase IIb clinical trial of CV9104 in patients with prostate cancer, the start of construction of an industrial scale GMP production facility with 30 million dose/year capability, and the initiation of new clinical programs including those in collaboration with Boehringer Ingelheim and IAVI.

About CureVac AG

Founded in 2000 as a spin-off from the University of T?bingen in Germany, CureVac is a technology leader in the development of drugs that are based on Messenger RNA (mRNA). The company has more than 15 years of expertise in handling and optimizing this versatile molecule for medical purposes and has the most advanced product pipe-line and IP portfolio in the industry.

The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.

Since its inception, CureVac has received approximately $330 million (€300 million) in equity investments and entered into various collaborations with multinational corpora-tions and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, the Bill & Melinda Gates Foundation and IAVI.

In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac will start the construction of an industrial scale production facility with a capacity of 30 million doses per year.

For more information, please visit


Media Contacts

Verena Lauterbach, Senior Manager Communications
CureVac AG, Tübingen, Germany
T: +49 (0) 7071 9883 1756

Andrew Mielach, Vice President
Tiberend Strategic Advisors, New York
T: +1 212 375 2694

Ash Spiegelberg, Director
Brunswick Group, Dallas
T: +1 214 205 6805

Record changed: 2017-07-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for CureVac (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top